Walleye Capital
TVTX icon

Walleye Capital’s Travere Therapeutics TVTX Stock Holding History

Walleye Capital’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.9K Sell
402
-5,052
-93% -$151K ﹤0.01% 4133
2025
Q4 		$208K Sell
5,454
-59,687
-92% -$1.94M ﹤0.01% 3527
2025
Q3 		$1.56M Sell
65,141
-126,726
-66% -$2.38M 0.01% 1764
2025
Q2 		$2.84M Sell
191,867
-77,271
-29% -$1.28M 0.01% 1251
2025
Q1 		$4.82M Sell
269,138
-158,092
-37% -$3.21M 0.02% 812
2024
Q4 		$7.44M Sell
427,230
-61,223
-13% -$1.08M 0.02% 823
2024
Q3 		$6.83M Buy
488,453
+221,982
+83% +$2.31M 0.01% 945
2024
Q2 		$2.19M Buy
266,471
+254,096
+2,053% +$1.71M ﹤0.01% 2019
2024
Q1 		$95.4K Buy
+12,375
New +$104K ﹤0.01% 4419
2023
Q4 		– Sell
-32,899
Closed -$294K – 5539
2023
Q3 		$294K Sell
32,899
-700,963
-96% -$9.89M ﹤0.01% 3250
2023
Q2 		$11.3M Buy
733,862
+692,631
+1,680% +$12.6M 0.04% 348
2023
Q1 		$927K Sell
41,231
-465,852
-92% -$9.9M 0.01% 1210
2022
Q4 		$10.7M Buy
507,083
+168,659
+50% +$3.57M 0.19% 112
2022
Q3 		$8.34M Buy
338,424
+130,529
+63% +$3.37M 0.16% 138
2022
Q2 		$5.04M Buy
207,895
+41,375
+25% +$1.04M 0.14% 171
2022
Q1 		$4.29M Buy
166,520
+123,425
+286% +$3.28M 0.11% 188
2021
Q4 		$1.34M Buy
+43,095
New +$1.21M 0.04% 448
2021
Q3 		– Sell
-22,778
Closed -$332 – 1815
2021
Q2 		$332 Buy
22,778
+13,931
+157% +$275K 0.01% 896
2021
Q1 		$221 Buy
+8,847
New +$244K 0.01% 886
2020
Q1 		– Sell
-18,996
Closed -$269K – 1677
2019
Q4 		$269K Sell
18,996
-58,681
-76% -$750K 0.02% 986
2019
Q3 		$900K Buy
+77,677
New +$1.28M 0.05% 491

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Walleye Capital's TVTX Position: Q1 2026 in Review

Walleye Capital reduced its Travere Therapeutics (TVTX) stake by 93% in Q1 2026, selling an estimated $151K and leaving 402 shares worth $11.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4133.

Walleye Capital first reported a position in TVTX in Q3 2019 and has held it in 21 quarters since. The position peaked at $11.3M in Q2 2023. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Walleye Capital held 402 shares of Travere Therapeutics worth $11.9K as of Q1 2026.
  • Walleye Capital sold 5,052 Travere Therapeutics shares in Q1 2026, an estimated $151K.
  • Travere Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #4133 holding.
  • Walleye Capital first reported a position in Travere Therapeutics in Q3 2019 and has held it in 21 quarters since.
  • Walleye Capital's Travere Therapeutics position peaked at $11.3M in Q2 2023.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.